Poland· PL-100342097
Atywia Daily
A dienogest und estrogen product containing ethinylestradiolum + dienogestum, registered in Poland by Exeltis Poland Sp. z o.o.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Dienogest und estrogen is registered in 5 of 19 countries.
Countries holding a registration under ATC G03FA15 (dienogest und estrogen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Dienogest und estrogen · ATC G03FA15
5 / 19 countries
- Belgiumprice
- Czechiaprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Ethinylestradiolum + Dienogestum
- Manufacturer
- Exeltis Poland Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- G03FA15
- ATC class
- Dienogest und Estrogen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991280727
- gtin05909991280734
- gtin05909991280741
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dienogest und estrogen in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAIDEEVIVAX Pharmaceuticals, s.r.o., Povážská Bystrica
- GermanyAmobenaBiomo Pharma Gmbh
- SpainADIERIS 2 mg/0,03 mg COMPRIMIDO RECUBIERTO CON PELICULA EFGLaboratorios Cinfa S.A.
- SwitzerlandCemisiana 2 mg / 0.03 mg, FilmtablettenSandoz Pharmaceuticals AG
- FinlandCelimonaBayer Schering Pharma Oy
- FranceJEZTIQ 2 mg/0,02 mg, comprimé à libération prolongéeEXELTIS SANTE
- IrelandKelzy 2 mg/0.02 mg prolonged release tabletsExeltis Healthcare S.L.
- NetherlandsKelzyn 2mg/0,02 mg, tablet met verlengde afgifteExeltis Healthcare S.L
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Dienorette, Dienovel
- Belgium · Dienobel, Louise
- Bulgaria · Жанин
- Czechia · Aidee, Ayreen
- Germany · Amobena, Aristelle
- Denmark · Yana
- Estonia · Ammily, Jeanine
- Spain · Adieris, Ailyn Diario
- Finland · Yanulez
- France · Misolfa
- United Kingdom (Northern Ireland) · Dienogest/Ethinylestradiol, Serisima
- Croatia · Donella
- Hungary · Dienille, Mistral
- Ireland · Mistra, Raener
- Italy · Cemisiana, Dienestra
- Lithuania · Ammily, Jeanine
- Luxembourg · Dienobel, Louise
- Latvia · Ammily, Jeanine
- Netherlands · Ethinylestradiol/Dienogest Mithra, Misolfa
- Norway · Yana
- Portugal · Denille, Dienogest + Etinilestradiol Leon Farma
- Slovakia · Aidee, Dienorette
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f57a0cac-8c6f-43ed-92c9-ec0bb3aa92d4 GET /v1/drugs/f57a0cac-8c6f-43ed-92c9-ec0bb3aa92d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "0,03 mg + 2 mg",
"packaging": "05909991280727 ¦ Rp ¦ 116310\n28 tabl.\n05909991280734 ¦ Rp ¦ 116311\n84 tabl.\n05909991280741 ¦ Rp ¦ 116312\n168 tabl.",
"substance": "Ethinylestradiolum 0.03 mg + Dienogestum 2 mg",
"common_name": "Ethinylestradiolum + Dienogestum",
"pl_product_id": "100342097",
"pozwolenie_nr": "23262",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about dienogest und estrogen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.